,,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'enhertu', '$azn']
does what we've seen from destiny breast 04 already back enhertu approval in her2-low irrespective of er status? $azn $dskny #asco22
Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today.